



Supplementary Materials



Supplemental Figure S1. Individual tumor progression following intratumoral IL-15 complexes and/or systemic anti-PD-1 mAb therapy. (A,F) Schematic diagrams indicating the frequency and timing of IL-15 complex and anti-PD-1 administration. (B–J) Individual tumor progression was measured by tumor area (L × W) and responses in mice treated with PBS (B,G), IL-15 complex's (C,H), αPD-1 (D,I), αPD-1 (E,J), and IL-15 complexes (C,H). Data represent one of three experiments with five mice per group in (A–E) and twelve mice per group in (F–J).



Supplemental Figure S2. Combinatorial treatment with IL-15 complexes and anti-PD-1 therapy induces differential expression of genes involved in immune activation and metabolic pathways. Fold expression changes in genes isolated from total tumor RNA compared to the PBS control treatment group. (A) TCR and co-stimulatory signaling heat map. (B) Cytokine and chemokine signaling heat map. (C) Heat map of cytotoxicity-associated genes. (D) Heat map of hypoxia-associated gene score. (E) Arginine metabolism heat map. (F) Heat map of lysosomal degradation-related genes. (G) Heat map of Notch signaling associated genes score. Only Log2 fold change of genes with p -values < 0.01 are shown.